Organ Transplant Immunosuppressant Drugs Market Scope
Organ transplant immunosuppressant drugs are the group of drugs which are directed to minimize the chances of organ rejection after transplantation. It is important to have these drugs because when a person goes through the organ transplantation, the body identifies a foreign organ or tissues and start attacking or rejecting the organ. These immunosuppressant drugs help in diluting the immune system thus resulting in reducing the reaction towards the transplanted organ such as kidney, liver, heart, lungs, and pancreas. Increasing survival by organ transplanting of many patients as well as enhancing their quality of life is driving the market for organ transplant immunosuppressant drugs.
The market study is being classified by Type (Chemical Composition, Fungal Product and Biologics), by Application (Liver Transplant, Kidney Transplant and Other Organ Transplant) and major geographies with country level break-up.
The market for Organ Transplant Immunosuppressant Drugs is fragmented widely, major companies such as AstellasPharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche are seeking for approval strategy for the commercialization of their pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Organ Transplant Immunosuppressant Drugs market throughout the predicted period.
North China Pharmaceutical HuaSheng Co. (China), Roche (Switzerland), Catalent Pharma (United States), Genzyme (United States), Huadong Pharmaceutical (China), Cilag (Switzerland), Cinkate (United States), Nanjing HICIN (China), Livzon Pharmaceutical Group Inc. (China) and Sinopharm Chuan Kang Pharmaceutical (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Novartis (Switzerland) and AstellasIreland Co.,Ltd (Ireland).
AdvanceMarketAnalytics has segmented the market of Global Organ Transplant Immunosuppressant Drugs market by Type, Application and Region.
On the basis of geography, the market of Organ Transplant Immunosuppressant Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type , the sub-segment i.e. Antibodies will boost the Organ Transplant Immunosuppressant Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distributed Channels, the sub-segment i.e. Hospitals will boost the Organ Transplant Immunosuppressant Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
In November 2018, Temple University, in collaboration with Veloxis Pharmaceuticals, initiated phase 4 clinical trial for Tacrolimus Extended Release Oral Tablet to evaluate dosing strategies for de novo once-daily extended release tacrolimus (LCPT) in kidney transplant recipients.
Uniform State Laws promulgated the Uniform Anatomical Gift Act (UAGA) with the intent of promoting uniformity among states and simplifying the process of obtaining organs from deceased persons. The UAGA is not a federal law, but rather is a template that states can use in developing their own laws governing anatomical gifts. Each state and the District of Columbia adopted the 1968 UAGA (AOPO, 2017). Due to its universal adoption, the 1968 UAGA is sometimes mistaken as federal law.
- New Government Initiatives on Transplant Research Programs
- Growing Trend of Medical Tourism
- Introduction of the Artificial Organ
- Increased Incidence of Organ Failure
- Increasing Infections to the Organ While Transplanting
- Increasing Incidence of Chronic Diseases and the Demand for Organ Replacement
- Growing Adoption of Tissues Engineering In Organ Transplant for both Developed and Developing Nations
- High Cost of Organ Transplantation
- Lack of Availability of Organs
- Issue Related With Shortage of Organ Donor for Transplant
Key Target AudiencePharmaceutical Industries, Health care centers, Government and Research Organizations, Associations and Industrial Bodies, Research and Consulting Firms and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase